Resistance to both chemotherapy and radiotherapy can be influenced by various genetic mutations and alterations in cancer cells. While specific mutations can confer resistance to one or both treatment modalities, cross-resistance often involves complex mechanisms rather than single mutations. Here are some key factors and mutations associated with resistance:

1. **TP53 Mutations**: The TP53 gene encodes the p53 protein, which plays a crucial role in DNA damage response and apoptosis. Mutations in TP53 can lead to impaired apoptosis and increased survival of cancer cells following chemotherapy and radiotherapy.

2. **KRAS Mutations**: KRAS is an oncogene that, when mutated, can drive cancer progression and contribute to resistance to certain chemotherapeutic agents and radiotherapy by promoting cell survival pathways.

3. **EGFR Mutations**: Alterations in the EGFR gene can lead to resistance to targeted therapies and may also affect sensitivity to radiation by influencing cell proliferation and survival.

4. **BRCA1/2 Mutations**: While BRCA1/2 mutations are often associated with increased sensitivity to DNA-damaging agents, secondary mutations or reversion mutations can restore homologous recombination repair, leading to resistance to both chemotherapy and radiotherapy.

5. **PI3K/AKT/mTOR Pathway Alterations**: Mutations or activation of components in this pathway can promote cell survival and proliferation, contributing to resistance to both chemotherapy and radiotherapy.

6. **Mismatch Repair Deficiency (MMR)**: Defects in the mismatch repair system can lead to microsatellite instability and resistance to certain chemotherapeutic agents, and may also affect radiotherapy outcomes.

7. **Multidrug Resistance (MDR) Genes**: Overexpression of MDR genes, such as ABCB1 (P-glycoprotein), can lead to efflux of chemotherapeutic drugs and potentially affect sensitivity to radiation by altering drug accumulation and cellular stress responses.

8. **Epigenetic Changes**: Methylation and histone modification can alter gene expression patterns, leading to resistance mechanisms that affect both chemotherapy and radiotherapy.

Cross-resistance is often the result of a combination of these genetic and epigenetic changes, along with alterations in cell cycle regulation, DNA repair capacity, and apoptotic pathways. Understanding the specific mutations and mechanisms in individual tumors is crucial for developing effective treatment strategies and overcoming resistance.